|
|
|
|
|
|
|
Positive
|
Late |
Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint) |
death, ↓20.0%, p=0.44 |
Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19 |
| Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality. |
|
Positive
|
Late treatment study
|
| Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint) |
| Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19 |
| Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality.
death, ↓20.0%, p=0.44
no improvement, ↓35.0%, p<0.0001, risk of no improvement at day 28
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
Late |
Flisiak et al., medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint) |
death, ↓48.9%, p=0.18 |
Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study |
| Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant). |
|
Positive
|
Late treatment study
|
| Flisiak et al., medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint) |
| Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study |
| Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant).
death, ↓48.9%, p=0.18, all patients
death, ↓58.0%, p=0.13, SpO2<95%
no improvement, ↓56.5%, p=0.01, no clinical improvement
(odds ratio converted to relative risk)
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
Late |
Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint) |
death, ↓47.0%, p<0.001 |
Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository |
| Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients showing 47% reduction in progression from ARDS to mortality. |
|
Positive
|
Late treatment study
|
| Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint) |
| Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository |
| Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients showing 47% reduction in progression from ARDS to mortality.
death, ↓47.0%, p<0.001
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Negative
|
Late |
SOLIDARITY Trial Consortium, medRxiv, doi:10.1101/2020.10.15.20209817 (Preprint) |
death, ↓5.0%, p=0.53 |
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results |
| WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) Remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50.
Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13. |
|
Negative
|
Late treatment study
|
| SOLIDARITY Trial Consortium, medRxiv, doi:10.1101/2020.10.15.20209817 (Preprint) |
| Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results |
| WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) Remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50.Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13.
death, ↓5.0%, p=0.53
death, ↓14.0%, p=0.13, non-ventilated patients
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
Late |
Beigel et al., NEJM, doi:10.1056/NEJMoa2007764 (Peer Reviewed) |
death, ↓27.0%, p=0.07 |
Remdesivir for the Treatment of Covid-19 — Final Report |
| RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001.
Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio H.. |
|
Positive
|
Late treatment study
|
| Beigel et al., NEJM, doi:10.1056/NEJMoa2007764 (Peer Reviewed) |
| Remdesivir for the Treatment of Covid-19 — Final Report |
RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001.Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio HR 0.73 [0.52-1.03].
![]()
death, ↓27.0%, p=0.07
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
Late |
Spinner et al., JAMA, doi:10.1001/jama.2020.16349 (Peer Reviewed) |
death, ↓34.9%, p=0.50 |
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial |
| Late stage (median 8 days from symptom onset) RCT 584 patients with moderate COVID-19 showing (non-statistically significant) lower mortality.
5-day remdesivir had significantly higher odds of a better clinical status distribution on the.. |
|
Positive
|
Late treatment study
|
| Spinner et al., JAMA, doi:10.1001/jama.2020.16349 (Peer Reviewed) |
| Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial |
| Late stage (median 8 days from symptom onset) RCT 584 patients with moderate COVID-19 showing (non-statistically significant) lower mortality.5-day remdesivir had significantly higher odds of a better clinical status distribution on the 7-point ordinal scale, odds ratio OR 1.65, p = 0.02. The difference for 10-day remdesivir was not statistically significant, p=0.18.
death, ↓34.9%, p=0.50, 5 or 10 day remdesivir vs. control 28 day mortality
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Meta
|
Late |
Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531
(Peer Reviewed) (meta analysis) |
death, ↓36.0%, p=0.02 |
Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials |
| Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175). |
|
Meta
|
Late treatment study
|
| Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531
(Peer Reviewed) (meta analysis) |
| Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials |
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).
![]()
death, ↓36.0%, p=0.02
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Inconc.
|
Late |
Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed) |
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 |
| RCT of remdesivir for 5 or 10 days with no placebo control group, showing no significant differences between 5 and 10 day treatment.
NCT04292899 |
|
Inconc.
|
Late treatment study
|
| Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed) |
| Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 |
RCT of remdesivir for 5 or 10 days with no placebo control group, showing no significant differences between 5 and 10 day treatment.NCT04292899
![]()
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Inconc.
|
Late |
Wang et al., Lancet, doi:10.1016/S0140-6736(20)31022-9 (Peer Reviewed) |
death, ↑8.6%, p=1.00 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial |
| Small RCT with 237 hospitalized patients in China with severe COVID-19, not showing statistically significant benefits. 158 treatment patients and 79 control patients.
While too small for significance, the subgroup treated within 10 days.. |
|
Inconc.
|
Late treatment study
|
| Wang et al., Lancet, doi:10.1016/S0140-6736(20)31022-9 (Peer Reviewed) |
| Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial |
Small RCT with 237 hospitalized patients in China with severe COVID-19, not showing statistically significant benefits. 158 treatment patients and 79 control patients.While too small for significance, the subgroup treated within 10 days showed reduced mortality RR 0.76, p = 0.58, and reduced median time to clinical improvement of 18 days vs. 23 days, hazard ratio 1.52 [0.95-2.43].
![]()
death, ↑8.6%, p=1.00, all patients
death, ↓24.3%, p=0.58, <10 days from symptoms
death, ↑47.6%, p=0.76, >10 days from symptoms
|
|
Source
Study Page
Submit Corrections or Comments
|
